Covaxin trials on track, 2nd dose given to volunteers at Rohtak PGIMS

Sunit Dhawan

Tribune News Service

Rohtak, October 8

Second dose of Covaxin – the indigenous Covid vaccine – has been given to volunteers under the Phase II of the clinical human trials at Rohtak PGIMS. As per the project investigators, the trials are going well and no adverse effects have been reported from any volunteer so far.

“After the administration of the second dose to all volunteers under Phase II trials and subject to positive outcome of their test reports, the Phase III of the clinical human trials will begin soon,” said Dr Ramesh Verma, a co-investigator of the project.

In Phase I, two doses of Covaxin were given to healthy volunteers in the age-group of 18-55 years, while in the Phase II, two doses of the vaccine have been given to different volunteers in the age-group of 12-65 years.

While only healthy volunteers were involved in the Phase I, the volunteers who have controlled diabetes, hypertension or asthma etc have been involved in the Phase II of the trials.

Meanwhile, apart from the launch of the post-Covid clinic for the benefit of the recovered Covid patients, modalities are also being worked out for the creation of a Covid-sampling site in the waiting area of the trauma centre.

Prof (Dr) Pushpa Dahiya, the newly appointed Medical Superintendent of PGIMS, inspected the site today and directed the officials concerned to take necessary measures to ensure that the suspected Covid patients did not face any inconvenience.

“As of now, the samples are being taken near the old casualty wing, due to which the chances of the spread of the infection is high. Hence, the sample-collection facility is being shifted to the trauma centre waiting area,” she said.

Join Whatsapp Channel of The Tribune for latest updates.